Physician profile
Jean E Molinary
NPI 1730179060
$8,167.15
in general payments reported to CMS, 2019-2025
48 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $1,046 · 2021: $650 · 2022: $1,402 · 2023: $1,463 · 2024: $1,808 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $903.36 | 2019-2024 | Tepezza, Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $896.66 | 2019-2025 | |
| Lilly USA, LLC | $778.07 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $701.78 | 2020-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $456.39 | 2021-2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $380.59 | 2021-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $338.10 | 2021-2022 | |
| Novo Nordisk INC | $294.51 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $274.36 | 2019-2024 | |
| Insulet Corporation | $273.15 | 2019-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $217.23 | 2020-2022 | |
| Antares Pharma, INC. | $213.70 | 2019-2022 | |
| Radius Health, INC. | $196.11 | 2020-2024 | Tymlos |
| Dexcom, INC. | $170.60 | 2022-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $140.50 | 2024 | Ilet Bionic Pancreas |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Molinary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.